DESTINY-Breast03 Phase 3 Study Results
DESTINY-Breast03: PFS by BICR1-3
100-
Progression-Free Survival Probability, %
T
40-
60-
80
80-
20-
Censor
T-DXD (n = 261)
DESTINY-Breast03
mPFS, mo (95% CI)
12-mo PFS rate, %
(95% CI)
HR (95% CI)
T-DXd
NR (18.5-NE)
75.8
(69.8-80.7)
T-DM1
6.8 (5.6-8.2)
34.1
(27.7-40.5)
0.28 (0.22-0.37)
P=7.8 × 10-22
T-DM1 (n=263)
2 3
4
Patients Still at Risk:
55
17
-6
Median duration of follow-up: T-DXd, 16.2 months; T-DM1, 15.3 months
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Time, months
T-DXd (261) 261 256 250 244 240 224 214 202 200 183 168 164 150 132 112 105 79 64 53 45 36 29 25 19 10 6 5 3 2 0
T-DM1 (263) 263 252 200 163 155 132 108 96 93 78 65 60 51 43 37 34 29 23 21 16 12 8 6 4 1 1 1 1 1 1 1 1 0
BICR, blinded independent central review; HR, hazard ratio; mPFS, median progression-free survival; NE, not estimable; NR, not reached; PFS, progression-free survival; T-DM1, trastuzumab emtansine;
T-DXd, trastuzumab deruxtecan.
1. Cortès J et al. N Engl J Med. 2022:386:1143-1154. 2. Cortés J et al. N Engl J Med. 2022; 2022;386(supplement). 3. Hurvitz SA et al. Presented at: San Antonio Breast Cancer Symposium 2021; December 7-10,
2021. Presentation GS3-01.
ESMO BC 2022 #1630 Oral
From New England Journal of Medicine, Cortés J et al, Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer, Vol. 386, Pages 1143-1154.
Copyright 2022 Massachusetts Medical Society. Reprinted with permission [pending] from Massachusetts Medical Society.
39
Ο
Daiichi-SankyoView entire presentation